Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15092589 | 1.00 | GRM5 (0.58) | GRM5HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL13316190 | 0.92 | GRM5 (0.64) | GRM5HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5724695 | 0.85 | GRM5 (0.59) | GRM5SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6180675 | 0.82 | GRM5 (0.55) | GRM5SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL5121718 | 0.82 | GRM5 (0.55) | GRM5SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL14197774 | 0.81 | ALDH1A1 (0.67) | HPGDSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12385822 | 0.81 | ALDH1A1 (0.67) | HPGDSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4702196 | 0.81 | GRM5 (0.64) | GRM5SMN1; SMN2ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL12683472 | 0.81 | SMN1; SMN2 (0.66) | HPGDSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL15841157 | 0.81 | SMN1; SMN2 (0.66) | HPGDSMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-9018244-B2 | Benzopyran compounds, compositions and uses thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | ESR2, GPER1, ESR1 | GRM5 383/4885HPGD 1227/4885SMN1; SMN2 3420/4885 |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | ESR2, GPER1, ESR1 | GRM5 383/4885HPGD 1227/4885SMN1; SMN2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.